Celularity (CELU) Competitors $2.94 +0.02 (+0.68%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CELU vs. LOTZ, MVST, NGNE, ATYR, FATE, PYXS, BMEA, TRVI, BNTC, and ACBShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include CarLotz (LOTZ), Microvast (MVST), Neurogene (NGNE), Atyr PHARMA (ATYR), Fate Therapeutics (FATE), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), Trevi Therapeutics (TRVI), Benitec Biopharma (BNTC), and Aurora Cannabis (ACB). Celularity vs. CarLotz Microvast Neurogene Atyr PHARMA Fate Therapeutics Pyxis Oncology Biomea Fusion Trevi Therapeutics Benitec Biopharma Aurora Cannabis Celularity (NASDAQ:CELU) and CarLotz (NASDAQ:LOTZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, community ranking, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Do insiders & institutionals believe in CELU or LOTZ? 19.0% of Celularity shares are held by institutional investors. Comparatively, 23.6% of CarLotz shares are held by institutional investors. 20.7% of Celularity shares are held by company insiders. Comparatively, 24.8% of CarLotz shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is CELU or LOTZ more profitable? CarLotz has a net margin of -35.92% compared to Celularity's net margin of -264.30%. CarLotz's return on equity of -62.06% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Celularity-264.30% -92.48% -20.76% CarLotz -35.92%-62.06%-40.45% Does the MarketBeat Community believe in CELU or LOTZ? Celularity received 3 more outperform votes than CarLotz when rated by MarketBeat users. Likewise, 42.11% of users gave Celularity an outperform vote while only 26.32% of users gave CarLotz an outperform vote. CompanyUnderperformOutperformCelularityOutperform Votes842.11% Underperform Votes1157.89% CarLotzOutperform Votes526.32% Underperform Votes1473.68% Which has more risk & volatility, CELU or LOTZ? Celularity has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, CarLotz has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Does the media prefer CELU or LOTZ? In the previous week, Celularity had 5 more articles in the media than CarLotz. MarketBeat recorded 5 mentions for Celularity and 0 mentions for CarLotz. Celularity's average media sentiment score of 0.77 beat CarLotz's score of 0.08 indicating that Celularity is being referred to more favorably in the media. Company Overall Sentiment Celularity Positive CarLotz Neutral Which has better earnings and valuation, CELU or LOTZ? CarLotz has higher revenue and earnings than Celularity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$22.77M2.84-$196.29MN/AN/ACarLotz$258.53M0.07-$39.88M-$0.86-0.17 SummaryCarLotz beats Celularity on 7 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.19M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.8587.8613.46Price / Sales2.84374.821,228.8287.66Price / Cash0.3952.5939.5136.27Price / Book1.3910.216.946.30Net Income-$196.29M$153.61M$119.12M$225.93M7 Day Performance30.67%-2.00%-1.84%-1.32%1 Month Performance39.67%-7.47%-3.65%0.60%1 Year Performance43.62%31.80%31.64%26.23% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.5369 of 5 stars$2.94+0.7%N/A+42.7%$64.19M$22.77M0.00220News CoverageLOTZCarLotzN/A$0.15flatN/A+0.0%$17.72M$258.53M-0.17492MVSTMicrovast2.0335 of 5 stars$0.58-6.5%$4.50+675.9%-55.4%$202.35M$306.62M0.002,006Analyst ForecastGap DownNGNENeurogene2.936 of 5 stars$15.33-11.0%$60.83+296.8%N/A$255.95MN/A0.0090Analyst ForecastAnalyst RevisionNews CoverageATYRAtyr PHARMA2.8572 of 5 stars$2.99-1.6%$19.25+543.8%N/A$255.18M$350,000.00-3.1856FATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradeNews CoveragePYXSPyxis Oncology1.0178 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A-3.7160News CoverageGap UpHigh Trading VolumeBMEABiomea Fusion3.4326 of 5 stars$6.28-2.2%$30.50+385.7%-39.1%$232.65MN/A-1.5750TRVITrevi Therapeutics3.4138 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A-6.3020BNTCBenitec Biopharma2.2984 of 5 stars$10.66+7.9%$22.60+112.0%+202.8%$229.38M$80,000.000.0020Positive NewsHigh Trading VolumeACBAurora Cannabis0.6402 of 5 stars$4.24+1.4%N/A-11.0%$229.24M$200.35M0.001,073 Related Companies and Tools Related Companies LOTZ Competitors MVST Competitors NGNE Competitors ATYR Competitors FATE Competitors PYXS Competitors BMEA Competitors TRVI Competitors BNTC Competitors ACB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CELU) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
